Artiva Biotherapeutics, Inc. financial data

Symbol
ARTV on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
5505 Morehouse Drive, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 24.3M shares
Common Stock, Value, Issued 3K USD
Weighted Average Number of Shares Outstanding, Basic 18.9M shares +2242%
Weighted Average Number of Shares Outstanding, Diluted 18.9M shares +171%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 13.5M USD +3.51%
General and Administrative Expense 4.81M USD +73.1%
Operating Income (Loss) -18.3M USD -270%
Nonoperating Income (Expense) 863K USD +84.4%
Net Income (Loss) Attributable to Parent -17.5M USD -255%
Earnings Per Share, Basic -0.92 USD/shares -107%
Earnings Per Share, Diluted -0.92 USD/shares -157%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 55.9M USD -15.2%
Cash, Cash Equivalents, and Short-term Investments 200M USD
Accounts Receivable, after Allowance for Credit Loss, Current 569K USD
Assets, Current 151M USD
Property, Plant and Equipment, Net 6.86M USD
Operating Lease, Right-of-Use Asset 14.4M USD
Other Assets, Noncurrent 298K USD
Assets 226M USD
Accounts Payable, Current 1.22M USD
Employee-related Liabilities, Current 4.81M USD
Accrued Liabilities, Current 8.34M USD
Liabilities, Current 13.3M USD
Operating Lease, Liability, Noncurrent 11.2M USD
Other Liabilities, Noncurrent 73K USD
Liabilities 24.6M USD
Accumulated Other Comprehensive Income (Loss), Net of Tax 338K USD
Retained Earnings (Accumulated Deficit) -231M USD
Stockholders' Equity Attributable to Parent 201M USD
Liabilities and Equity 226M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Common Stock, Shares Authorized 700M shares
Common Stock, Shares, Issued 424K shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 56.1M USD -15.1%
Operating Lease, Liability 14.8M USD
Depreciation 600K USD 0%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -17.3M USD -251%
Lessee, Operating Lease, Liability, to be Paid 17.9M USD
Property, Plant and Equipment, Gross 12.2M USD
Operating Lease, Liability, Current 3.61M USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.42M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 4.01M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3.1M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.52M USD
Preferred Stock, Shares Authorized 10M shares
Share-based Payment Arrangement, Expense 1.91M USD +39.1%